比阿培南治疗呼吸科患者急性细菌性感染的临床研究
|
摘要
目的探讨比阿培南不同剂量用于呼吸科患者院内急性细菌性感染治疗的临床效果和安全性,为临床用药进行指导。方法选取2011年4月-2013年12月发生医院急性细菌性感染的呼吸科患者174例,随机分为A组患者85例,给予比阿培南每次0.3g,每天两次静脉滴注;B组患者89例,给予比阿培南每次0.6g,每天两次静脉滴注,比较两组患者疗效,数据采用SPSS 13.0软件进行统计分析。结果 A组患者痊愈、显效、总有效率、细菌清除率分别为31.76%、21.18%、52.94%和55.29%,B组分别为43.82%、34.83%、78.65%和82.02%;B组不良反应发生率明显高于A组,两组比较差异有统计学意义(P<0.05)。结论加大比阿培南治疗用量,虽然可以提高合并医院急性细菌性感染的呼吸科患者的临床治疗效果和细菌清除率,但是也增加患者治疗过程中不良反应的发生率,因此临床应用中应谨慎权衡利弊,根据患者状况制定合理治疗方案。
OBJECTIVE To observe the clinical efficacy and safety of different doses of biapenem in treatment of acute bacterial infection in the patients of respiratory medicine department so as to provide guidance for clinical use of antibiotics.METHODS A total of 174 patients with acute bacterial infections who were treated in the respiratory medicine department from Apr 2011 to Dec 2013 were enrolled in the study and randomly divided into the group A with 85 cases and the group B with 89 cases.The group A was treated with intravenous drip of biapenem,twice a day,0.3g each time;the group B was given intravenous drip of biapenem,twice a day,0.6g each time.The therapeutic effect was observed and compared between the two groups,and the statistical analysis was performed with the use of SPSS 13.0software.RESULTS The cure rate was 31.76%in the group A,43.82%in the group B;the effective rate was 21.18%in the group A,34.83% in the group B;the total effective rate was 52.94% in the group A,78.65%in the group B;the bacterial clearance rate was 55.29%in the group A,82.02%in the group B.The incidence of adverse reactions was significantly higher in the group B than in the group A(P<0.05).CONCLUSION Although the increase of dose of biapenem can improve the clinical effect on clinical treatment of the patients with acute bacterial infection and raise the bacterial clearance rate,it may also lead to the increase of incidence of adverse reactions,thus the advantages and disadvantages of clinical use of biapenem should be weighed,and the rational treatment programs should be formulated based on the patient's condition.
OBJECTIVE To observe the clinical efficacy and safety of different doses of biapenem in treatment of acute bacterial infection in the patients of respiratory medicine department so as to provide guidance for clinical use of antibiotics.METHODS A total of 174 patients with acute bacterial infections who were treated in the respiratory medicine department from Apr 2011 to Dec 2013 were enrolled in the study and randomly divided into the group A with 85 cases and the group B with 89 cases.The group A was treated with intravenous drip of biapenem,twice a day,0.3g each time;the group B was given intravenous drip of biapenem,twice a day,0.6g each time.The therapeutic effect was observed and compared between the two groups,and the statistical analysis was performed with the use of SPSS 13.0software.RESULTS The cure rate was 31.76%in the group A,43.82%in the group B;the effective rate was 21.18%in the group A,34.83% in the group B;the total effective rate was 52.94% in the group A,78.65%in the group B;the bacterial clearance rate was 55.29%in the group A,82.02%in the group B.The incidence of adverse reactions was significantly higher in the group B than in the group A(P<0.05).CONCLUSION Although the increase of dose of biapenem can improve the clinical effect on clinical treatment of the patients with acute bacterial infection and raise the bacterial clearance rate,it may also lead to the increase of incidence of adverse reactions,thus the advantages and disadvantages of clinical use of biapenem should be weighed,and the rational treatment programs should be formulated based on the patient's condition.
引文
[1]晏丽,娄世锋.比阿培南治疗中性粒细胞减少伴发热的64例恶性血液病患者的疗效观察[J].重庆医学,2013,42(7):739-740.
[2]Yamada K,Yamamoto Y,Yanagihara K,et al.In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa[J].J Infect Chemother,2012,18(4):472-478.
[3]杨怡欣,陈喜林,肖秀斌,等.比阿培南治疗淋巴瘤化疗后Ⅳ度骨髓抑制合并重度感染的临床疗效观察[J].白血病·淋巴瘤,2013,22(5):282-283.
[4]Gomi K,Fujimura S,Fuse K,et al.Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in thenortheastern region of Japan in 2007[J].J Infect Chemother,2011,17(2):200-206.
[5]郭智,陈惠仁,何学鹏,等.比阿培南在血液科患者临床应用的有效性与安全性研究[J].中华医院感染学杂志,2011,21(10):2079-2081.
[6]Karino F,Deguchi N,Kanda H,et al.Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics[J].J Infect Chemother,2013,19(1):98-102.
[2]Yamada K,Yamamoto Y,Yanagihara K,et al.In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa[J].J Infect Chemother,2012,18(4):472-478.
[3]杨怡欣,陈喜林,肖秀斌,等.比阿培南治疗淋巴瘤化疗后Ⅳ度骨髓抑制合并重度感染的临床疗效观察[J].白血病·淋巴瘤,2013,22(5):282-283.
[4]Gomi K,Fujimura S,Fuse K,et al.Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in thenortheastern region of Japan in 2007[J].J Infect Chemother,2011,17(2):200-206.
[5]郭智,陈惠仁,何学鹏,等.比阿培南在血液科患者临床应用的有效性与安全性研究[J].中华医院感染学杂志,2011,21(10):2079-2081.
[6]Karino F,Deguchi N,Kanda H,et al.Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics[J].J Infect Chemother,2013,19(1):98-102.